Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review

Aim: To analyze the efficacy, safety and pharmacoeconomic aspects of using ocrelizumab in adult patients with relapsing/remitting multiple sclerosis (R/R MS).Materials and Methods. We used the commonly accepted PICo(S) questionnaire with the following specifics: the population – patients with R/R MS...

Descrición completa

Detalles Bibliográficos

Principais autores:	D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin
Formato:	Artigo
Idioma:	Russo
Publicado:	IRBIS LLC 2018-11-01
Series:	Фармакоэкономика
Assuntos:	ocrelizumab efficacy safety relapsing-remitting multiple sclerosis relapsing multiple sclerosis secondary progressive multiple sclerosis anti-b-cell therapy monoclonal antibodies
Acceso en liña:	https://www.pharmacoeconomics.ru/jour/article/view/261
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!